Metastasis Affecting Patents (Class 514/19.8)
-
Patent number: 11981753Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound YA-156, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.Type: GrantFiled: April 22, 2022Date of Patent: May 14, 2024Assignee: ShangPharma Innovation Inc.Inventors: Yvonne Angell, Yu Wu, Yan Wang, Weimin Liu, Kin Chiu Fong, Jie Wen, Yonghan Hu
-
Patent number: 11807660Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by compound 3, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.Type: GrantFiled: March 22, 2022Date of Patent: November 7, 2023Assignee: XDCEXPLORER (SHANGHAI) CO., LTD.Inventors: Yvonne Angell, Yu Wu, Yan Wang, Weimin Liu, Kin Chiu Fong, Jie Wen, Yonghan Hu
-
Patent number: 11427615Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by formula (1), and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.Type: GrantFiled: July 5, 2018Date of Patent: August 30, 2022Assignee: XDCEXPLORER (SHANGHAI) CO., LTD.Inventors: Yvonne Angell, Yun Wu, Yan Wang, Weimin Liu, Kin Chiu Fong, Jie Wen, Yonghan Hu
-
Patent number: 11365227Abstract: The present invention relates to a peptide derived from the defensin-3 from the red flour beetle Tribolium castaneum, to pharmaceutical compositions containing same, and to the use thereof as an antimicrobial in the treatment of infections caused by gram-positive bacteria, gram-negative bacteria and fungi. The invention also relates to the use of the peptide and pharmaceutical compositions containing same, in the treatment of cancer, particularly breast cancer. The compound described is a peptide derived from defensin-3 from the red flour beetle T. castaneum.Type: GrantFiled: December 21, 2018Date of Patent: June 21, 2022Inventors: María Dolores Real García, Carolina Rausell Segarra, Inmaculada García Robles, María Benito Jardón, Aída Robles Fort
-
Patent number: 11274349Abstract: Provided herein are methods for diagnosing cancer in a subject by determining the gene expression level of one or more genes in extracellular vesicles isolated from samples obtained from a subject.Type: GrantFiled: November 8, 2017Date of Patent: March 15, 2022Assignee: Cedars-Sinai Medical CenterInventors: Dolores Di Vizio, Valentina R. Minciacchi, Andrew Conley
-
Patent number: 11013775Abstract: Methodologies and apparatuses are provided for producing new anti-cancer compounds and compositions by placing mushrooms or mushroom mycelia in contact with cancer cells or tissues and harvesting secretions produced by the mushrooms or mushroom mycelia which will destroy cancer cells without harming normal cells and tissues. The anti-cancer compounds are administered to humans or other mammals for cancer treatment.Type: GrantFiled: November 15, 2017Date of Patent: May 25, 2021Assignee: Oral Roberts UniversityInventor: William P. Ranahan, II
-
Publication number: 20150133367Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.Type: ApplicationFiled: April 26, 2013Publication date: May 14, 2015Inventor: Doron C. Greenbaum
-
Patent number: 9018171Abstract: The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.Type: GrantFiled: November 14, 2013Date of Patent: April 28, 2015Assignee: Mycomagic Biotechnology Co., Ltd.Inventor: Jiunn-Liang Ko
-
Publication number: 20150110808Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.Type: ApplicationFiled: December 21, 2012Publication date: April 23, 2015Applicant: GLYCOMIMETICS, INC.Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
-
Patent number: 8999934Abstract: The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.Type: GrantFiled: August 9, 2010Date of Patent: April 7, 2015Assignee: Board of Regents, The University of Texas SystemInventors: Isaiah Fidler, Sun-jin Kim
-
Patent number: 8980250Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.Type: GrantFiled: June 8, 2011Date of Patent: March 17, 2015Inventor: Meng Kwoon Sim
-
Publication number: 20150071986Abstract: The present invention concerns a pharmaceutical composition comprising virtosomes isolated from non-dividing cells or the medium in which the cells are grown, for use in the inhibition of tumour growth and/or prevention of metastases.Type: ApplicationFiled: May 29, 2014Publication date: March 12, 2015Applicant: The Foundation for Biomedical Research of La Paz University Hospital (FIBHULP)Inventors: Damián GARCIA-OLMO, Mariano Garcia-Arranz, Luz Vega Clemente, Peter Brian Gahan, Maurice Stroun
-
Publication number: 20150023920Abstract: The invention includes a method of preventing or treating metastasis in a subject diagnosed with cancer, the method comprising determining whether at least one gene encoding one or more proteins is upregulated in a cancer tissue sample from the subject as compared to the level of expression of the at least one gene in a non-cancer control sample of the same tissue, and, if the at least one gene is upregulated in the cancer tissue sample from the subject, administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more protein depleting agents.Type: ApplicationFiled: March 13, 2013Publication date: January 22, 2015Applicant: Drexel UniversityInventors: Alessandro Fatatis, Michael Russell, Qingxin (Cindy) Lui
-
Patent number: 8920809Abstract: This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject.Type: GrantFiled: August 17, 2010Date of Patent: December 30, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: Joseph M. Dirienzo
-
Publication number: 20140370027Abstract: The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor.Type: ApplicationFiled: March 30, 2012Publication date: December 18, 2014Applicants: Cincinnati Childrens's Hospital Medical Center, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Jeffrey W. Pollard, Richard A. Lang
-
Publication number: 20140369987Abstract: The invention relates to the use of peptides corresponding to dermaseptin B2 or fragments thereof for treating proliferative diseases such as cancer or ocular lesions, and to pharmaceutical compositions containing such peptides.Type: ApplicationFiled: August 29, 2014Publication date: December 18, 2014Inventors: Jean DELBE, Mohamed AMICHE, Ali LADRAM, Cecile GALANTH, Pierre NICOLAS, Yamina HAMMA, Johanna Allegonda Anna VAN ZOGGEL, Jose COURTY
-
Patent number: 8911736Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.Type: GrantFiled: March 8, 2011Date of Patent: December 16, 2014Assignee: Genzyme CorporationInventors: Jay Harper, Scott M. Lonning, Frank James Hsu
-
Publication number: 20140363522Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.Type: ApplicationFiled: May 13, 2014Publication date: December 11, 2014Inventors: Ernst LENGYEL, Kristin NIEMAN, Hilary KENNY
-
Publication number: 20140364377Abstract: The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Inventors: Christopher J. Kirk, Jing Jiang
-
Patent number: 8901276Abstract: The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.Type: GrantFiled: December 19, 2011Date of Patent: December 2, 2014Assignee: The Regents of the University of MichiganInventors: Thomas D. Wang, Sharon Miller, Bishnu Joshi
-
Publication number: 20140342995Abstract: The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.Type: ApplicationFiled: April 14, 2014Publication date: November 20, 2014Applicant: Neumedicines, Inc.Inventor: Lena A. BASILE
-
Publication number: 20140328858Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.Type: ApplicationFiled: May 2, 2014Publication date: November 6, 2014Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
-
Publication number: 20140322332Abstract: The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.Type: ApplicationFiled: April 1, 2014Publication date: October 30, 2014Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Donald W. KUFE, Surender KHARBANDA
-
Publication number: 20140314841Abstract: The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.Type: ApplicationFiled: April 18, 2014Publication date: October 23, 2014Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human ServInventors: Raj K. Puri, Bharat H. Joshi, Benjamin Rubin
-
Publication number: 20140302057Abstract: The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.Type: ApplicationFiled: April 7, 2014Publication date: October 9, 2014Inventors: Indu PARIKH, Kenneth B. Adler
-
Publication number: 20140294851Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.Type: ApplicationFiled: April 1, 2013Publication date: October 2, 2014Inventor: MARK QUANG NGUYEN
-
Publication number: 20140286952Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.Type: ApplicationFiled: March 30, 2012Publication date: September 25, 2014Applicant: Board of Supervisors for the University of Louisia System, acting on behalf of the University of LouInventor: Girish V. Shah
-
Publication number: 20140248260Abstract: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.Type: ApplicationFiled: January 10, 2012Publication date: September 4, 2014Applicant: CLEVELAND BIOLABS, INC.Inventors: Anatoli Gleiberman, Lyudmila Burdelya, Andrei Gudkov
-
Patent number: 8822442Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.Type: GrantFiled: October 28, 2005Date of Patent: September 2, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
-
Publication number: 20140243276Abstract: A method of using a Smac mimetic and pharmaceutical compositions thereof.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: David Weng, Srinivas Chunduru, Martin Graham
-
Patent number: 8808698Abstract: The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (?4?1, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis.Type: GrantFiled: February 5, 2007Date of Patent: August 19, 2014Assignee: The Regents of the University of CaliforniaInventors: Judith Varner, Barbara Garmy-Susini
-
Patent number: 8802627Abstract: The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a ?-amyloid precursor protein molecule-derived domain having an activity of selectively inhibiting matrix metalloproteinase-2 and a tissue inhibitor of metalloproteinase capable of binding to latent matrix metalloproteinase. Also disclosed are a pharmaceutical composition, a cancer metastasis and/or angiogenesis inhibitor, a therapeutic and/or prophylactic for cardiovascular diseases, and a matrix metalloproteinase-2 inhibitor, each of which comprises the fusion molecule.Type: GrantFiled: October 5, 2009Date of Patent: August 12, 2014Assignee: Oriental Yeast Co., Ltd.Inventor: Shouichi Higashi
-
Publication number: 20140206621Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: November 8, 2013Publication date: July 24, 2014Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Patent number: 8785392Abstract: A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.Type: GrantFiled: April 13, 2010Date of Patent: July 22, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Kiwon Jo, Donghee Lee, Jung Yu, Ji Hyun Park, Chan-Woong Park, Eun Jin Kim, Yun Jung Park
-
Publication number: 20140193334Abstract: Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C1-6alkylene-phenyl-NH—C(O)—R15, folic acid, ?v?3 integrin RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein R15 is a peptide.Type: ApplicationFiled: August 30, 2012Publication date: July 10, 2014Inventors: Ulrich Bierbach, Song Ding
-
Publication number: 20140186364Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1, ECOLE NORMALE SUPERIEURE DE LYON, CENTRE LEON BERARDInventors: Patrick Etienne-Roger MEHLEN, Servane Marie-Séverine Tauszig-Delamasure, Céline Jacqueline-Andrée Delloye, Jimena Bouzas-Rodriguez
-
Patent number: 8748388Abstract: Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof useful as antitumour agents.Type: GrantFiled: December 10, 2008Date of Patent: June 10, 2014Assignee: Pharma Mar, S.A.Inventors: Judit Tulla-Puche, Eleonora Marcucci, Núria Bayó-Puxan, Fernando Albericio, Maria del Carmen Cuevas Marchante
-
Patent number: 8716235Abstract: Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression.Type: GrantFiled: April 10, 2013Date of Patent: May 6, 2014Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Jeffrey W. Pollard
-
Publication number: 20140121169Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: ApplicationFiled: December 20, 2013Publication date: May 1, 2014Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Patent number: 8709998Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.Type: GrantFiled: April 21, 2004Date of Patent: April 29, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
-
Publication number: 20140113857Abstract: The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to ?-catenin in vitro, in cellulo, and in vivo, disrupting the BCL-9/?-catenin interaction, and thereby interfering with deregulated Wnt/?-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.Type: ApplicationFiled: April 16, 2012Publication date: April 24, 2014Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Ruben Carrasco, Gregory H. Bird
-
Patent number: 8697629Abstract: A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an ?6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. 17 to modulate a FAK signal transduction pathway for a sufficient period of time to treat the disease. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes measuring the effect of these polypeptides on FAK signal transduction activity; wherein a change in FAK signal transduction activity is indicative of said aberrant cell migration or invasion. A method of diagnosing a condition characterized by aberrant cell migration and/or invasion includes imaging FAK signal transduction activity in the presence of these polypeptides.Type: GrantFiled: March 4, 2011Date of Patent: April 15, 2014Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Malcolm Finlayson, Bassam B. Damaj
-
Publication number: 20140088016Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.Type: ApplicationFiled: May 17, 2012Publication date: March 27, 2014Applicant: University of Florida Research Foundation, Inc.Inventor: Hendrik Luesch
-
Publication number: 20140088022Abstract: The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.Type: ApplicationFiled: September 16, 2013Publication date: March 27, 2014Applicant: Merck Patent GmbHInventors: Alfred Jonczyk, Clemens Kuehn, Kerstin Seemann, Christoph Saal, Gerald Scholz, Soenke Petersen, Harald Untenecker, Michael Lange
-
Publication number: 20140080764Abstract: The invention relates to a drug and/or pharmaceutical composition for treating metastatic tumors, in particular of malignant melanoma, above all of stage IV malignant melanoma, and to the use of said drug, in particular the use of said drug in select patient populations.Type: ApplicationFiled: April 10, 2012Publication date: March 20, 2014Applicant: Cytavis Biopharma GmbHInventors: Hans Lentzen, Klaus Wittholn
-
Publication number: 20140072574Abstract: A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.Type: ApplicationFiled: September 10, 2013Publication date: March 13, 2014Applicant: National Tsing Hua UniversityInventors: Margaret Dah-Tsyr Chang, Lin-Shien Fu, Shun-Lung Fang
-
Publication number: 20140072558Abstract: The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.Type: ApplicationFiled: April 3, 2012Publication date: March 13, 2014Applicants: ANTIBODY AND RECEPTOR THERAPEUTICS CO., LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Young Woo Park, Ki Won Jo, Donghee Lee, Eun Kyung Lee, Seil Jang, Chan Woong Park, Dong-Jin Kim, Hye Nan Kim, Yun Jung Park, Jae Eun Park, Ji Hyun Park, Seok Ho Yoo, Myeoung Hee Jang
-
Publication number: 20140066375Abstract: The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.Type: ApplicationFiled: March 2, 2012Publication date: March 6, 2014Inventors: Young Woo Park, Ki Won Jo, Kyu Won Cho, Ji Hyun Park, Soon Sil Hyun, Yun Jung Park
-
Patent number: 8653031Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.Type: GrantFiled: October 30, 2006Date of Patent: February 18, 2014Assignee: Universidade Federal de Minas GeraisInventors: Rubén Dario Sinisterra Millán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
-
Publication number: 20140044741Abstract: The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide.Type: ApplicationFiled: February 9, 2012Publication date: February 13, 2014Inventors: Stefan Offermanns, Jakub Swiercz, Thomas Worzfeld